Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) have earned an average rating of "Moderate Buy" from the six analysts that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $27.50.

A number of brokerages have issued reports on KMTS. The Goldman Sachs Group lowered their price target on Kestra Medical Technologies from $24.00 to $23.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 16th. Wolfe Research assumed coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They issued an "outperform" rating and a $29.00 target price on the stock. Wells Fargo & Company assumed coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They issued an "overweight" rating and a $28.00 target price on the stock. Stifel Nicolaus assumed coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They issued a "buy" rating and a $28.00 target price on the stock. Finally, Bank of America initiated coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They issued a "buy" rating and a $30.00 target price on the stock.

Institutional Investors Weigh In On Kestra Medical Technologies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quarry LP acquired a new stake in Kestra Medical Technologies during the first quarter worth $33,000. Virtu Financial LLC acquired a new stake in Kestra Medical Technologies during the first quarter worth $210,000. Armistice Capital LLC acquired a new stake in Kestra Medical Technologies during the first quarter worth $312,000. Zimmer Partners LP acquired a new stake in Kestra Medical Technologies during the first quarter worth $374,000. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Kestra Medical Technologies in the first quarter valued at $457,000.

Kestra Medical Technologies Stock Performance

Shares of KMTS stock traded down $0.37 during mid-day trading on Wednesday, reaching $15.41. The stock had a trading volume of 263,675 shares, compared to its average volume of 254,013. The business has a fifty day moving average of $20.04. Kestra Medical Technologies has a 1-year low of $14.08 and a 1-year high of $26.15.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last issued its earnings results on Monday, April 14th. The company reported ($1.25) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.61). During the same period in the previous year, the firm posted ($1.18) earnings per share.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.